Scilex Holding Company (SCLX) Gross Margin
- Gross margin · 12 months: Value 348.33%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 348.33% | Gross profit / revenue. Period ending 2026-06-30. $110.10M ÷ $31.61M × 100 ≈ 348.33% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 110.10M USD | Gross Profit |
| Revenue | 31.61M USD | |
| Cost of products and services | 79.16M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $110.10M | $31.61M | $79.16M | 348.33% |
| 2026-03-31 | $133.80M | $33.86M | $100.68M | 395.13% |
| 2025-12-31 | $125.80M | $30.25M | $96.26M | 415.83% |
| 2025-09-30 | (m) | $40.36M | (m) | (m) |
| 2025-06-30 | (m) | $44.24M | (m) | (m) |
| 2025-03-31 | (m) | $50.71M | (m) | (m) |
| 2024-12-31 | (m) | $56.59M | (m) | (m) |
| 2024-09-30 | (m) | $55.15M | (m) | (m) |
| 2024-06-30 | (m) | $50.83M | (m) | (m) |
| 2024-03-31 | (m) | $47.05M | (m) | (m) |
| 2023-12-31 | (m) | $46.74M | (m) | (m) |
| 2023-09-30 | (m) | $45.20M | (m) | (m) |
| 2023-06-30 | (m) | $46.46M | (m) | (m) |
| 2023-03-31 | (m) | $41.80M | (m) | (m) |
| 2022-12-31 | (m) | $38.03M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $31.32M | (m) | (m) |
| 2020-12-31 | (m) | $23.56M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |